Chitra Subramanian1, Rui Kuai2, Qing Zhu1, Peter White1, James J Moon2, Anna Schwendeman3, Mark S Cohen4. 1. Department of Surgery, University of Michigan, Ann Arbor, MI. 2. Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI; Biointerfaces Institute, University of Michigan, Ann Arbor, MI. 3. Biointerfaces Institute, University of Michigan, Ann Arbor, MI; Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI. 4. Department of Surgery, University of Michigan, Ann Arbor, MI; Department of Pharmacology, University of Michigan, Ann Arbor, MI. Electronic address: cohenmar@med.umich.edu.
Abstract
BACKGROUND: Chemotherapeutic strategies for adrenocortical carcinoma (ACC) carry substantial toxicities. Cholesterol is critical for ACC cell growth and steroidogenesis, and ACC cells overexpress scavenger receptor BI, which uptakes cholesterol from circulating high-density lipoprotein (HDL) cholesterol. We hypothesize that cholesterol-free synthetic-HDL nanoparticles (sHDL) will deplete cholesterol and synergize with chemotherapeutics to achieve enhanced anticancer effects at lesser (less toxic) drug levels. METHODS: The antiproliferative efficacy of ACC cells for the combinations of sHDL with chemotherapeutics was tested by Cell-Titer Glo. Cortisol levels were measured from the culture media. Effects on steroidogenesis was measured by real-time polymerase chain reaction (RT-PCR). Induction of apoptosis was evaluated by flow cytometry. RESULTS: Combination Index (CI) for sHDL and either etoposide (E), cisplatin (P), or mitotane (M) demonstrated synergy (CI < 1) for antiproliferation. Alone or in combination with the chemotherapy drugs, sHDL was able to decrease cortisol production by 70-90% compared with P alone or controls (P < .01). RT-PCR indicated inhibition of steroidogenic enzymes for sHDL (P < .01 vs no sHDL). Combination therapy with sHDL increased apoptosis by 30-50% compared with drug or sHDL alone (P < .03), confirmed by a decrease in the mitochondrial potential. CONCLUSION: sHDL can act synergistically and lessen the amount of M/E/P needed for anticancer efficacy in ACC in part owing to cholesterol starvation. This novel treatment strategy warrants further investigation translationally.
BACKGROUND: Chemotherapeutic strategies for adrenocortical carcinoma (ACC) carry substantial toxicities. Cholesterol is critical for ACC cell growth and steroidogenesis, and ACC cells overexpress scavenger receptor BI, which uptakes cholesterol from circulating high-density lipoprotein (HDL) cholesterol. We hypothesize that cholesterol-free synthetic-HDL nanoparticles (sHDL) will deplete cholesterol and synergize with chemotherapeutics to achieve enhanced anticancer effects at lesser (less toxic) drug levels. METHODS: The antiproliferative efficacy of ACC cells for the combinations of sHDL with chemotherapeutics was tested by Cell-Titer Glo. Cortisol levels were measured from the culture media. Effects on steroidogenesis was measured by real-time polymerase chain reaction (RT-PCR). Induction of apoptosis was evaluated by flow cytometry. RESULTS: Combination Index (CI) for sHDL and either etoposide (E), cisplatin (P), or mitotane (M) demonstrated synergy (CI < 1) for antiproliferation. Alone or in combination with the chemotherapy drugs, sHDL was able to decrease cortisol production by 70-90% compared with P alone or controls (P < .01). RT-PCR indicated inhibition of steroidogenic enzymes for sHDL (P < .01 vs no sHDL). Combination therapy with sHDL increased apoptosis by 30-50% compared with drug or sHDL alone (P < .03), confirmed by a decrease in the mitochondrial potential. CONCLUSION: sHDL can act synergistically and lessen the amount of M/E/P needed for anticancer efficacy in ACC in part owing to cholesterol starvation. This novel treatment strategy warrants further investigation translationally.
Authors: Chitra Subramanian; Huaping Zhang; Robert Gallagher; Gary Hammer; Barbara Timmermann; Mark Cohen Journal: World J Surg Date: 2014-06 Impact factor: 3.352
Authors: A Berruti; E Baudin; H Gelderblom; H R Haak; F Porpiglia; M Fassnacht; G Pentheroudakis Journal: Ann Oncol Date: 2012-10 Impact factor: 32.976
Authors: P G Yancey; M de la Llera-Moya; S Swarnakar; P Monzo; S M Klein; M A Connelly; W J Johnson; D L Williams; G H Rothblat Journal: J Biol Chem Date: 2000-11-24 Impact factor: 5.157
Authors: Chitra Subramanian; Peter T White; Rui Kuai; Avinaash Kalidindi; Valerie P Castle; James J Moon; Barbara N Timmermann; Anna Schwendeman; Mark S Cohen Journal: Surgery Date: 2018-05-09 Impact factor: 3.982
Authors: Ton Wang; Chitra Subramanian; Minzhi Yu; Peter T White; Rui Kuai; Jaquelyn Sanchez; James J Moon; Barbara N Timmermann; Anna Schwendeman; Mark S Cohen Journal: Surgery Date: 2019-07-29 Impact factor: 3.982
Authors: Rui Kuai; Chitra Subramanian; Peter T White; Barbara N Timmermann; James J Moon; Mark S Cohen; Anna Schwendeman Journal: Int J Nanomedicine Date: 2017-09-06
Authors: Ricardo Costa; Benedito A Carneiro; Fabio Tavora; Sachin G Pai; Jason B Kaplan; Young Kwang Chae; Sunandana Chandra; Peter A Kopp; Francis J Giles Journal: Oncotarget Date: 2016-07-19